Cure Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Investors
-
1
Cure Therapeutics General Information
Description
Developer of immuno-oncology therapies designed for patients with life-threatening conditions. The company's technology enhances natural killer cell potency through proprietary activation, expansion, and homing platforms, enabling healthcare providers to deliver automated point-of-care manufacturing for natural killer cell therapies, chimeric antigen receptor T-cell therapies, tumor-infiltrating lymphocytes, cellular vaccines, and infectious disease immunotherapies.
Contact Information
Corporate Office
- Rm 601 156
- Gwanggyo-ro, Yeongtong-gu
- Suwon, 16506
- South Korea
Corporate Office
- Rm 601 156
- Gwanggyo-ro, Yeongtong-gu
- Suwon, 16506
- South Korea
Cure Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Later Stage VC | 01-Nov-2026 | Completed | Startup |
Cure Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Cure Therapeutics Patents
Cure Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023191559-A1 | Method for mass proliferation of activated natural killer cells, and use thereof | Inactive | 30-Mar-2022 | ||
| WO-2008027203-A2 | Medicated orthopedic support structures for treatment of damaged musculoskeletal tissue | Inactive | 28-Aug-2006 | ||
| WO-2008027203-A3 | Medicated orthopedic support structures for treatment of damaged musculoskeletal tissue | Inactive | 28-Aug-2006 | ||
| WO-2007143185-A2 | Transdermal treatment of tendinopathy using glyceryl trinitrite | Inactive | 01-Jun-2006 | ||
| WO-2007143185-A3 | Transdermal treatment of tendinopathy using glyceryl trinitrite | Inactive | 01-Jun-2006 | A61K9/0014 |
Cure Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| KGROUND Ventures | Venture Capital | Minority |
Cure Therapeutics Investments (1)
Cure Therapeutics’s most recent deal was a Joint Venture with Joint Venture (Orgenesis & Cure Therapeutics) for . The deal was made on 09-Dec-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Joint Venture (Orgenesis & Cure Therapeutics) | 09-Dec-2020 | Joint Venture | Drug Discovery |
Cure Therapeutics FAQs
-
When was Cure Therapeutics founded?
Cure Therapeutics was founded in 2017.
-
Where is Cure Therapeutics headquartered?
Cure Therapeutics is headquartered in Suwon, South Korea.
-
What industry is Cure Therapeutics in?
Cure Therapeutics’s primary industry is Biotechnology.
-
Is Cure Therapeutics a private or public company?
Cure Therapeutics is a Private company.
-
What is Cure Therapeutics’s current revenue?
The current revenue for Cure Therapeutics is .
-
Who are Cure Therapeutics’s investors?
KGROUND Ventures has invested in Cure Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
